Aandoeningen die als ondersteuning van de therapie/ingreep bloedtransfusie vereisen No specific disease
Conditions
Interventions
Standard ABO-D compatible versus extended (C,c,E,e,K,Fya,Jka and S) compatible
red blood cell products. Both have equal standard product-specifications
Sponsors
Sanquin Bloedbank
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: The general transfusion population >18 years requiring an elective RBC transfusion
Exclusion criteria
Exclusion criteria: Patients younger than 18 years Patients with an a priori indication for matched transfusions (congenital hemolytic anemia*s, immune hemolytic anaemia, females of (pre-) childbearing age) Patients with a positive DAT Patients who, based on the local pre-operative blood-ordering list, require more than 4 RBC units during surgery. Incapacitated subjects or patients who cannot understand the information.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of alloimmunization in transfusion patients through preventive donor matching for clinically relevant antibodies compared to standard matching in patients stratified for high and random risk alloimmunization | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Cost-analysis for current serologic screen and match strategy compared to preventive matching strategy in the 2 strata of patients 2. Investigate transfusion and/or other medical treatment delay in case of RBC alloimmunization 3. Obtain data on clinical and genetic factors associated with RBC alloimmunization | — |
Countries
Netherlands
Outcome results
None listed